|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Southwest Oncology Group National Cancer Institute (NCI) |
|---|---|
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00003018 |
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with stage II or stage III pancreatic cancer that has not been surgically removed.
| Condition | Intervention | Phase |
|---|---|---|
|
Pancreatic Cancer |
Drug: dipyridamole Drug: fluorouracil Drug: leucovorin calcium Drug: mitomycin C |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | A Phase II Trial of Infusional 5-Fluorouracil (5-FU), Calcium Leucovorin (LV), Mitomycin-C (Mito-C), and Dipyridamole (D) in Patients With Locally Advanced Unresected Pancreatic Adenocarcinoma |
| Estimated Enrollment: | 55 |
| Study Start Date: | September 1997 |
OBJECTIVES: I. Assess the one year overall survival rate of patients with advanced, unresectable pancreatic cancer treated with fluorouracil, leucovorin, mitomycin and dipyridamole. II. Assess the response rate in this group of patients. III. Evaluate the frequency and severity of the toxic effects associated with this therapy. IV. Assess the rate of resectability in patients who respond to therapy.
OUTLINE: All patients undergo surgical placement of an indwelling central venous line. Patients receive fluorouracil IV by continuous infusion on days 1-28, leucovorin calcium IV on days 1, 8, 15, and 22, oral dipyridamole on days 1-28, and mitomycin IV every 6 weeks starting on day 1. Treatment repeats every 6 weeks for 4 courses. Patients with a partial or complete response are reevaluated for possible surgical resection. Resected patients resume chemotherapy 4-8 weeks after surgery for an additional 16 weeks. Patients are followed every 6 months for 2 years, then annually until death.
PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS: Histologically or cytologically proven stage II or III pancreatic adenocarcinoma Ductal adenocarcinoma Mucinous noncystic carcinoma Signet ring cell carcinoma Adenosquamous carcinoma Undifferentiated (anaplastic) carcinoma Mixed ductal-endocrine carcinoma Well differentiated adenocarcinoma Moderately well or poorly differentiated adenocarcinoma Undifferentiated ductal carcinoma Must have unresectable and localized disease Measurable or evaluable disease
PATIENT CHARACTERISTICS: Age: Not specified Performance status: SWOG 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not pregnant or nursing Fertile patients must use effective contraception Loss of no greater than 15% of actual body weight Oral intake of greater than 1,200 calories per day No other malignancy within the past 5 years except adequately treated basal or squamous cell skin cancer, carcinoma in situ of the cervix, or any stage I or II cancer that is currently in complete remission
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior systemic chemotherapy for pancreatic cancer Endocrine therapy: Not specified Radiotherapy: No prior radiation therapy for pancreatic cancer Surgery: At least 2 weeks since prior surgical bypass procedure and recovered
Contacts and Locations
Show 84 Study Locations| Study Chair: | William H. Isacoff, MD | Jonsson Comprehensive Cancer Center |
More Information
| Study ID Numbers: | CDR0000065599, SWOG-S9700 |
| Study First Received: | November 1, 1999 |
| Last Updated: | July 23, 2008 |
| ClinicalTrials.gov Identifier: | NCT00003018 History of Changes |
| Health Authority: | United States: Federal Government |
|
stage II pancreatic cancer stage III pancreatic cancer duct cell adenocarcinoma of the pancreas |
|
Antimetabolites Vasodilator Agents Immunologic Factors Pancreatic Neoplasms Leucovorin Mitomycins Pancrelipase Anti-Bacterial Agents Vitamins Mitomycin Micronutrients Alkylating Agents Endocrine Gland Neoplasms Vitamin B Complex Digestive System Neoplasms |
Endocrine System Diseases Trace Elements Cardiovascular Agents Folinic Acid Immunosuppressive Agents Calcium, Dietary Digestive System Diseases Phosphodiesterase Inhibitors Fluorouracil Pancreatic Diseases Gastrointestinal Neoplasms Platelet Aggregation Inhibitors Endocrinopathy Adenocarcinoma Dipyridamole |
|
Antimetabolites Vasodilator Agents Antimetabolites, Antineoplastic Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Pancreatic Neoplasms Physiological Effects of Drugs Hematologic Agents Leucovorin Antibiotics, Antineoplastic Mitomycins Neoplasms by Site Vitamins Therapeutic Uses |
Mitomycin Micronutrients Alkylating Agents Nucleic Acid Synthesis Inhibitors Endocrine Gland Neoplasms Vitamin B Complex Digestive System Neoplasms Growth Substances Endocrine System Diseases Enzyme Inhibitors Cardiovascular Agents Immunosuppressive Agents Pharmacologic Actions Neoplasms Digestive System Diseases |
